ARBS: H1 2025 saw 35.5% revenue growth, 143% EBITDA increase, and robust net profit margin

About this update from Arterra Bioscience Spa

Production value grew 35.5% to €3.1M in H1 2025, with EBITDA up 143% and net profit at €1.1M. Strong cash position, improved margins, and ongoing R&D support a positive outlook, with sales momentum continuing into H2.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Arterra Bioscience Spa